The company raised $28 million through a Series B financing, which was led by Morningside, and included support from additional new investors -- First Spark Ventures and ExSight Ventures – and existing investors -- Berkeley Catalyst Fund and Pandect Bioventures. The company is engineering disruptive medicines that optimize how and where disease mechanisms are targeted to produce the most significant clinical impact. The company has won numerous awards and grants, including from the National Cancer Institute (NCI), National Institutes of Health (NIH), National Eye Institute (NEI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), among others. The biopolymers and bioactive molecules are interchangeable, which enables Valitor to assemble novel macromolecular entities that are engineered to overcome a multitude of specific drug design challenges for their target indications. We are also thrilled that Valitor was able to attract such high caliber talent as Steve. Also importantly, our platform technology can be applied to a variety of disease types, and we already have a strong pipeline behind our lead candidate.” Valitor is positioned to rapidly advance a pipeline of therapies, initially focused on clinically-validated mechanisms for indications where there are opportunities to address unmet patient/clinician needs with new medicines that offer optimized pharmacological properties. Valitor has been able to leverage validated assets to generate new compounds optimized to treat additional indications in ophthalmology, thereby de-risking the company’s pipeline expansion.